Prothena (PRTA) Price & Analysis

Compare

659 Followers

PRTA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.32 - $22.83

Previous CloseN/A

Volume58.73K

Average Volume (3M)992.20K

Market Cap

$449.48M

Enterprise Value-$34.92M

Total Cash (Recent Filing)$371.44M

Total Debt (Recent Filing)$9.78M

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Oct 30, 2025

EPS Estimate

-0.69

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.34

Shares Outstanding53,829,983

10 Day Avg. Volume959,548

30 Day Avg. Volume992,203

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.08

Enterprise Value/Revenue-3.38

Enterprise Value/Gross Profit-3.70

Enterprise Value/Ebitda0.14

Forecast

1Y Price Target

$15.00

Price Target Upside75.23% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Strategic PartnershipsMAD data showing robust plaque reduction while maintaining lower ARIA rate can be encouraging for strategic partnership.

Therapeutic PotentialThe decision to investigate 200 mg and 400 mg doses in a once-monthly regimen reflects confidence in PRX012’s therapeutic potential.

Bears Say

Clinical Trial FailureThe Phase III study in AL amyloidosis failed for the second time, which was based on a post-hoc analysis of the first Phase III study previously stopped for futility.

Financial StabilityThere are concerns about further cash burn in a difficult capital markets environment, impacting the company's financial stability.

Prothena News

Prothena price target lowered to $15 from $81 at Piper Sandler

Piper Sandler lowered the firm’s price target on Prothena (PRTA) to $15 from $81 and keeps an Overweight...

10h ago

PRTA

Prothena announces Novo Nordisk to advance coramitug into Phase 3

Prothena (PRTA) announced that Novo Nordisk (NVO) communicated during their second quarter 2025 earnings call on August 6...

22d ago

NVO

PRTA

Prothena reports Q2 EPS ($2.34), consensus ($1.79)

Reports Q2 revenue $4.4M, consensus $5.4M. Net cash used in operating and investing activities was $46.4 million in...

24d ago

PRTA

Prothena Announces Promising Phase 1 Results for PRX012

The latest update is out from Prothena ( ($PRTA) ). On August 27, 2025, Prothena announced results from...

23h ago

PRTA

Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk

An announcement from Prothena ( ($PRTA) ) is now available. On August 6, 2025, Prothena announced that its...

22d ago

PRTA

Prothena’s Strategic Initiatives and Promising Alzheimer’s Pipeline Drive Buy Rating

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Prothena, with a...

23d ago

PRTA

Prothena Reports Q2 2025 Financial Results and Pipeline Progress

Prothena Corporation ( ($PRTA) ) has released its Q2 earnings. Here is a breakdown of the information Prothena...

24d ago

PRTA

PRTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Prothena Corporation (PRTA) is scheduled to report 2nd quarter earnings on 08/04/2025, after the market closes. Regarding Q2...

26d ago

PRTA

Prothena Secures Leadership with New Executive Agreements

The latest update is out from Prothena ( ($PRTA) ). On July 30, 2025, Prothena Biosciences Inc entered...

29d ago

PRTA

Closing Bell Movers: GMS up 15% on takeover proposal from QXO

Ahead of Juneteenth market holiday on Thursday, U.S. equity future are little changed in the opening hour of...

2M ago

APG

GMS

Prothena Announces Major Workforce Reduction to Cut Costs

Prothena ( ($PRTA) ) has provided an update. On June 18, 2025, Prothena Corporation plc announced a significant...

2M ago

PRTA

Prothena up 3% after announcing corporate restructuring, cash burn update

16:37 EDT Prothena (PRTA) up 3% after announcing corporate restructuring, cash burn update Published first on TheFly –...

2M ago

PRTA

Prothena sees 2025 net cash burn from operating/investing at $170M-$178M

Based on the reorganization, Prothena (PRTA) is “revising its full year 2025 financial guidance and expects its 2025...

2M ago

PRTA

Prothena Chief Regulatory Officer Karp, Chief People Officer Ford to depart

On June 18, 2025, Prothena (PRTA) “announced that in connection with the workforce reduction, the employment of Carol...

2M ago

PRTA

PRTA FAQ

What was Prothena’s price range in the past 12 months?

Prothena lowest stock price was $4.32 and its highest was $22.83 in the past 12 months.

What is Prothena’s market cap?

Prothena’s market cap is $449.48M.

When is Prothena’s upcoming earnings report date?

Prothena’s upcoming earnings report date is Oct 30, 2025 which is in 63 days.

How were Prothena’s earnings last quarter?

Prothena released its earnings results on Aug 04, 2025. The company reported -$2.34 earnings per share for the quarter, missing the consensus estimate of -$1.254 by -$1.086.

Is Prothena overvalued?

According to Wall Street analysts Prothena’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Prothena pay dividends?

Prothena does not currently pay dividends.

What is Prothena’s EPS estimate?

Prothena’s EPS estimate is -0.69.

How many shares outstanding does Prothena have?

Prothena has 53,829,983 shares outstanding.

What happened to Prothena’s price movement after its last earnings report?

Prothena reported an EPS of -$2.34 in its last earnings report, missing expectations of -$1.254. Following the earnings report the stock price went up 1.297%.

Which hedge fund is a major shareholder of Prothena?

Currently, no hedge funds are holding shares in PRTA

Prothena Stock Smart Score

Neutral

Fundamentals

Return on Equity

-66.85%

Trailing 12-Months

Asset Growth

-38.18%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Prothena

Prothena Corporation plc is a biotechnology company focused on discovering and developing novel therapeutics for the treatment of neurodegenerative diseases and cancer. The company leverages its expertise in protein misfolding and aggregation to create innovative therapies, primarily in the areas of amyloid-related diseases such as Alzheimer's and Parkinson's disease, along with other protein misfolding disorders. Prothena's pipeline includes several clinical-stage programs, highlighting its commitment to addressing unmet medical needs with its proprietary technology platform.

Prothena (PRTA) Earnings & Revenues

Historic Earnings Reports

PRTA Stock 12 Month Forecast

Average Price Target

$15.00

▲(75.23% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","30":"$30","9.75":"$9.75","16.5":"$16.5","23.25":"$23.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,9.75,16.5,23.25,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.81,8.516923076923076,10.223846153846154,11.93076923076923,13.637692307692308,15.344615384615384,17.05153846153846,18.75846153846154,20.465384615384615,22.172307692307694,23.87923076923077,25.586153846153845,27.29307692307692,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.81,7.4399999999999995,8.07,8.7,9.33,9.96,10.59,11.22,11.850000000000001,12.48,13.11,13.740000000000002,14.370000000000001,{"y":15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.81,6.593846153846154,6.377692307692308,6.161538461538461,5.945384615384615,5.729230769230769,5.513076923076923,5.296923076923077,5.0807692307692305,4.864615384615385,4.648461538461539,4.432307692307692,4.216153846153846,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.27,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.81,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >